Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) insider David M. Spencer sold 10,000 shares of the company’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) opened at 11.98 on Monday. Bellicum Pharmaceuticals, Inc. has a 52 week low of $9.71 and a 52 week high of $23.11. The company has a 50-day moving average of $11.88 and a 200-day moving average of $12.96. The firm’s market capitalization is $396.57 million.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by $0.10. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.09 million. Bellicum Pharmaceuticals had a negative return on equity of 63.42% and a negative net margin of 17,957.31%. Bellicum Pharmaceuticals’s revenue was up 39.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.56) earnings per share. On average, equities analysts forecast that Bellicum Pharmaceuticals, Inc. will post ($2.84) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/insider-selling-bellicum-pharmaceuticals-inc-blcm-insider-sells-115400-00-in-stock/1445153.html.

BLCM has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price target on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. BidaskClub cut shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Jefferies Group LLC lowered their price target on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 9th. Finally, Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $28.43.

Institutional investors have recently modified their holdings of the company. Foresite Capital Management III LLC bought a new position in shares of Bellicum Pharmaceuticals during the first quarter worth $11,328,000. LMR Partners LLP bought a new position in shares of Bellicum Pharmaceuticals during the first quarter worth $3,339,000. Sphera Funds Management LTD. bought a new position in shares of Bellicum Pharmaceuticals during the first quarter worth $2,468,000. Vanguard Group Inc. boosted its position in shares of Bellicum Pharmaceuticals by 17.8% in the first quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock worth $13,100,000 after buying an additional 160,151 shares in the last quarter. Finally, Monashee Investment Management LLC bought a new position in shares of Bellicum Pharmaceuticals during the first quarter worth $1,974,000. 64.96% of the stock is currently owned by hedge funds and other institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.